Análise da influência do momento do ingresso em creches no desenvolvimento infantil

Este estudo objetivou analisar a relação entre a idade de ingresso nos programas de educação na primeira infância (EPI) e o desenvolvimento infantil. Trata-se de um estudo transversal com dados oriundos da Coorte de Nascimentos da Região Oeste de São Paulo, Brasil. Realizou-se o acompanhamento de crianças nascidas no Hospital Universitário da Universidade de São Paulo durante 36 meses, entre os anos de 2012 e 2014, e de seus cuidadores respondentes durante a onda de seguimentos dos 36 meses de idade (realizada entre os anos de 2015 e 2017). O desenvolvimento infantil foi mensurado pelo instrumento Engle Scale do Projeto Regional de Indicadores de Desenvolvimento Infantil (PRIDI). Os programas de EPI foram avaliados em relação a sua qualidade. Foram utilizadas como variáveis expositivas as características sociais das crianças e dos seus cuidadores, bem como as características do contexto econômico e familiar. A amostra foi composta por 472 crianças e cuidadores. Observou-se que o ingresso na creche entre 13 e 29 meses foi o mais frequente. Quando considerados isoladamente, observou-se que uma maior idade de ingresso esteve associada com maior escore de desenvolvimento [β = 0,21, IC95%: 0,02; 0,40, p = 0,027]. Após a inclusão das variáveis de ajuste nos modelos de regressão, observou-se que estar inscrito em instituição do tipo privada, tempo total de aleitamento materno, horas trabalhadas fora de casa pelo cuidador principal e o controle inibitório foram determinantes para explicar o desenvolvimento infantil aos 36 meses na amostra. A idade de ingresso mais tardia nos programas de EPI pode ter efeito positivo sobre o desenvolvimento infantil aos 36 meses de idade, porém esses achados precisam ser ponderados

Differences in children and adolescents with SARS-CoV-2 infection: a cohort study in a Brazilian tertiary referral hospital

OBJECTIVES: To compare demographic/clinical/laboratory/treatments and outcomes among children and adolescents with laboratory-confirmed coronavirus disease 2019 (COVID-19). METHODS: This was a cross-sectional study that included patients diagnosed with pediatric COVID-19 (aged <18 years) between April 11, 2020 and April 22, 2021. During this period, 102/5,951 (1.7%) of all admissions occurred in neonates, children, and adolescents. Furthermore, 3,962 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection samples were processed in patients aged <18 years, and laboratory-confirmed COVID-19 occurred in 155 (4%) inpatients and outpatients. Six/155 pediatric patients were excluded from the study. Therefore, the final group included 149 children and adolescents (n=97 inpatients and 52 outpatients) with positive SARS-CoV-2 results. RESULTS: The frequencies of sore throat, anosmia, dysgeusia, headache, myalgia, nausea, lymphopenia, pre-existing chronic conditions, immunosuppressive conditions, and autoimmune diseases were significantly reduced in children and adolescents (p<0.05). Likewise, the frequencies of enoxaparin use (p=0.037), current immunosuppressant use (p=0.008), vasoactive agents (p=0.045), arterial hypotension (p<0.001), and shock (p=0.024) were significantly lower in children than in adolescents. Logistic regression analysis showed that adolescents with laboratory-confirmed COVID-19 had increased odds ratios (ORs) for sore throat (OR 13.054; 95% confidence interval [CI] 2.750-61.977; p=0.001), nausea (OR 8.875; 95% CI 1.660-47.446; p=0.011), and lymphopenia (OR 3.575; 95% CI 1.355-9.430; p=0.010), but also had less hospitalizations (OR 0.355; 95% CI 0.138-0.916; p=0.032). The additional logistic regression analysis on patients with preexisting chronic conditions (n=108) showed that death as an outcome was significantly associated with pediatric severe acute respiratory syndrome (SARS) (OR 22.300; 95% CI 2.341-212.421; p=0.007) and multisystem inflammatory syndrome in children (MIS-C) (OR 11.261; 95% CI 1.189-106. 581; p=0.035). CONCLUSIONS: Half of the laboratory-confirmed COVID-19 cases occurred in adolescents. Individuals belonging to this age group had an acute systemic involvement of SARS-CoV-2 infection. Pediatric SARS and MIS-C were the most important factors associated with the mortality rate in pediatric chronic conditions with COVID-19

Economic analysis of chemo radiotherapy in head and neck cancer

INTRODUÇÃO: O presente trabalho teve como objetivo elaborar análise custoefetividade do esquema de quimiorradioterapia com cisplatina (estratégia 2) comparado ao tratamento radioterápico (estratégia 1) para pacientes portadores de CECCP localmente avançado não elegíveis para tratamento cirúrgico. MÉTODOS: levantamos dados prospectivos de 33 pacientes na estratégia 2 e dados retrospectivos de 29 pacientes tratados no HC-FMUSP e Hospital A.C. Camargo, (estratégia 1). Consideramos a tabela de reembolso do Sistema Único de Saúde (perspectiva SUS) e custos do HC-FMUSP com honorários profissionais, medicamentos, demais insumos e depreciação de equipamentos (perspectiva Institucional). A medida de efetividade foi 1 ano de vida ganho, livre de progressão da doença (SLPD). Calculamos a Razão Incremental Custo Efetividade (RICE). RESULTADOS: 31% dos pacientes da estratégia 1 e 58% na estratégia 2) tiveram 1 ano de SLPD. Na perspectiva SUS o custo total por paciente na estratégia 1 foi de R$2.798,52 e R$ 4.938,11 na estratégia 2. Na perspectiva institucional os custos foram R$26.798,52 e R$ 5.040,79, respectivamente. A RICE na perspectiva SUS foi de R$7.924,00 reais por ano de vida ganho e R$ 8.912,71 na perspectiva institucional. CONCLUSÃO: nas duas perspectivas a estratégia 2 se mostrou custo-efetiva, sendo o custo incremental considerado aceitável, segundo diretrizes do Banco Mundial.INTRODUCTION: The present study aims to conduct a cost-effectiveness analysis comparing chemoradiotherapy with cisplatine and radiotherapy alone, to treat inoperative advanced head and neck cancer. METHODS: we collected data from 29 patients in a prospective study on chemoradiotherapy with cisplatin, conducted at Hospital das Clínicas HC-FMUSP,(strategy 2). For strategy 1, we collected retrospective data of 33 patients treated with radiotherapy at HC-FMUSP and Hospital A.C. Camargo. We considered only direct costs (personnel, drugs, material and equipment depreciation). We considered, the National Health Service (SUS) reimbursement parameters as the National Security System perspective, and HC-FMUSP costs as the institutional perspectives. We measured effectiveness as one year of diseasefree life gained. We collected costs and effectiveness data and calculated the cost-effectiveness incremental ratio ICER, which expresses additional costs per life year gained, in strategy 2, compared to strategy 1 RESULTS: 31.0% of the patients treated in strategy 1 lived more than 12 months, without disease progression, compared to 58.0% of the patients in strategy 2. According to SUS perspective, the total cost per patient in strategy 1) is R$2.798,52 and R$ 4.938,11 in strategy 2. Considering the institutional perspective, total costs are R$2.634,36, and R$ 5.040,79 respectively. In SUS perspective, the ICER ratio of strategy 2 compared to 1 is R$7.924,00 per lifes year gained. In the institutional perspective, ICER is R$ 8.912,71. We conducted a one way sensitivity analysis to verify our calculations. CONCLUSION: Chemoradioterapy with cisplatin proved more cost-effective than radiotherapy. Using the World Bank guidelines, wich considers the countries GDP per capita an acceptable cost per additional year of life (R$ 12.491,00 in 2006), the incremental cost of both is acceptable

Relation between Birth Weight, Growth, and Subclinical Atherosclerosis in Adulthood

Background and Objectives. Adverse conditions in the prenatal environment and in the first years of life are independently associated with increased risk for cardiovascular disease. This paper aims to study the relation between birthweight, growth in the first year of life, and subclinical atherosclerosis in adults. Methods. 88 adults aged between 20 and 31 were submitted to sociodemographic qualities, anthropometric data, blood pressure measurements, metabolic profile, and evaluation of subclinical atherosclerosis. Results. Birthweight <2,500 grams (g) was negatively correlated with (a) increased waist-to-hip ratio (WHR), according to regression coefficient (RC) equal to −0.323, 95% CI [−0.571, −0.075] P<0.05; (b) diastolic blood pressure (RC = −4.744, 95% CI [−9.017, −0.470] P<0.05); (c) low HDL-cholesterol (RC = −0.272, 95% CI [−0.516, −0.029] P<0.05); (d) frequency of intima-media thickness (IMT) of left carotid >75th percentile (RC = −0.242, 95% CI [−0.476, −0.008] P<0.05). Birthweight >3,500 g was associated with (a) BMI >25.0 kg/m2, (RC = 0.317, 95% CI [0.782, 0.557] P<0.05); (b) increased waist circumference (RC = 0.284, 95% CI [0.054, 0.513] P<0.05); (c) elevated WHR (RC = 0.280, 95% CI [0.054, 0.505] P<0.05); (d) minimum subcutaneous adipose tissue (SAT) (RC = 4.354, 95% CI [0.821, 7.888] P<0.05); (e) maximum SAT (RC = 7.095, 95% CI [0.608, 13.583] P<0.05); (f) right lobe of the liver side (RC = 6.896, 95% CI [1.946, 11.847] P<0.001); (g) frequency’s right lobe of the liver >75th percentile (RC = 0.361, 95% CI [0.169, 0.552] P<0.001). Weight gain in the first year of life was inversely correlated with (a) mean IMT of left carotid (RC = −0.046, 95% CI [−0.086, −0.006] P<0.05; (b) frequency IMT of left carotid >75th percentile (RC = −0.253, 95% CI [−0.487, −0.018] P<0.05); (c) mean IMT (RC = −0.038, 95% CI [0.073, −0.002] P<0.05); (d) the frequency of the mean IMT >75th percentile (RC = −0.241, 95% CI [−0.442, −0.041] P<0.05). Conclusions. Adults birthweight <2,500 g and >3,500 g and with insufficient weight gain in the first year of life have showed different metabolic phenotypes, but all of them were related to subclinical atherosclerosis

The Intergenerational Effects on Birth Weight and Its Relations to Maternal Conditions, São Paulo, Brazil

Background and Objectives. Parents’ birth weight acts as a predictor for the descendant birth weight, with the correlation more strongly transmitted through maternal line. The present research aims to study the correlation between the child’s low or increased birth weight, the mother’s birth weight, and maternal conditions. Methods. 773 mother-infant binomials were identified with information on both the baby’s and the mother’s birth weight recorded. Group studies were constituted, dividing the sample according to birth weight (<2,500 grams (g) and ≥3,500 grams (g)). The length at birth was also studied in children ≤47.5 cm (lower quartile). Chi2 test or Fisher’s exact test, Spearman’s Rho, and odds ratio were performed in order to investigate the relation between the children’s weight and length at birth and the mothers’ and children’s variables. Results. The girls were heavier at birth than their mothers, with an average increase at birth weight between the generations of 79 g. The child’s birth weight <2,500 g did not show any correlation with maternal birth weight <2,500 g (Fisher 0.264; Spearman’s Rho 0.048; OR 2.1 and OR lower 0.7) or with maternal stature below the lower quartile (<157 cm) (Chi2 sig 0.323; with Spearman’s Rho 0.036; OR 1.5 and OR lower 0.7). The child’s low birth weight (<2,500 g) was lightly correlated with drug use by the mother during pregnancy (Fisher 0.083; Spearman’s Rho 0.080; OR 4.9 and OR lower 1.0). The child’s birth weight <2,500 g showed increased correlation with gestational age lower than 38 weeks and 3 days (Chi2 sig 0.002; Spearman’s Rho 0.113; OR 3.2 and OR lower 1.5). The child’s weight at birth ≥3,500 g showed strong correlation with maternal weight at birth ≥3,500 g (Chi2 sig 0; Spearman’s Rho +0.142; OR 0.5 and OR upper 0.7). It was also revealed that the higher the maternal prepregnancy BMI, the stronger the correlation with child’s birth weight ≥3,500 g ((maternal prepregnancy BMI>25.0 with Chi2 sig 0.013; Spearman’s Rho 0.09; OR 1.54 and OR upper 2.17) and (maternal prepregnancy BMI>30.0 with Chi2 sig 0 Spearman’s Rho 0.137; OR 2.58 and OR upper 4.26)). The child’s length at birth in the lower quartile (≤47.5 cm) showed strong correlation with drug use by the mother during pregnancy (Chi2 sig 0.004; Spearman’s Rho 0.105; OR 4.3 and OR lower 1.5). Conclusions. The mother’s increased weight at birth and the prenatal overweight or obesity were correlated with increased weight and length at birth of the newborn, coupled with the tendency of increasing birth weight between generations of mothers and daughters. Also, descendants with smaller length at birth are the children of women with the lowest statures